{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCMA+bispecific",
    "query": {
      "intervention": "BCMA bispecific"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCMA+bispecific&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T10:28:14.080Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05950113",
      "title": "CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Immunotherapy",
          "type": "OTHER"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-03-28",
      "completion_date": "2028-03-28",
      "has_results": false,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05950113"
    },
    {
      "nct_id": "NCT04649359",
      "title": "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab (PF-06863135)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 187,
      "start_date": "2021-02-02",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 21,
      "location_summary": "Beverly Hills, California • Irvine, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04649359"
    },
    {
      "nct_id": "NCT06993675",
      "title": "Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Talquetamab",
          "type": "DRUG"
        },
        {
          "name": "Teclistamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noffar Bar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-21",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Rochester, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06993675"
    },
    {
      "nct_id": "NCT07083960",
      "title": "OM336 in Autoimmune Cytopenias",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIHA - Warm Autoimmune Hemolytic Anemia",
        "AIHA - Cold Autoimmune Hemolytic Anemia",
        "ITP - Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "OM336",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lakefront Biotherapeutics West LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-08-01",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07083960"
    },
    {
      "nct_id": "NCT06215118",
      "title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Iberdomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-02-20",
      "completion_date": "2028-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 34,
      "location_summary": "Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06215118"
    },
    {
      "nct_id": "NCT07738822",
      "title": "A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia (ITP)",
        "Warm Autoimmune Hemolytic Anemia (WAIHA)"
      ],
      "interventions": [
        {
          "name": "Velinotamig specified dose on specified days.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cullinan Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 72,
      "start_date": "2026-12",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 1,
      "location_summary": "Webster, Texas",
      "locations": [
        {
          "city": "Webster",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07738822"
    },
    {
      "nct_id": "NCT07524634",
      "title": "Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyloid Light-chain Amyloidosis"
      ],
      "interventions": [
        {
          "name": "BCMA bispecific",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2026-08",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Cleveland, Ohio",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07524634"
    },
    {
      "nct_id": "NCT07280013",
      "title": "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma (MM)"
      ],
      "interventions": [
        {
          "name": "Cemsidomide",
          "type": "DRUG"
        },
        {
          "name": "Elranatamab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "C4 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-06",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 20,
      "location_summary": "Gilbert, Arizona • Sacramento, California • Santa Monica, California + 17 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07280013"
    },
    {
      "nct_id": "NCT05317416",
      "title": "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 854,
      "start_date": "2022-03-25",
      "completion_date": "2029-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 24,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317416"
    },
    {
      "nct_id": "NCT05565391",
      "title": "A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 508,
      "start_date": "2022-10-03",
      "completion_date": "2022-11-04",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-09-18T10:28:14.080Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565391"
    }
  ]
}